PRODUCT NEWS Nutramigen 1 and 2 with LGG®
Mead Johnson Nutrition announces new name and preparation instructions for Nutramigen 1 with LGG® and Nutramigen 2 with LGG® (previously Nutramigen LIPIL 1 & 2). Nutramigen with LGG® is an extensively hydrolysed formula to effectively manage the symptoms of infants with cow’s milk allergy. The addition of LGG®
to
Nutramigen LIPIL accelerates the acquisition of oral tolerance in infant with cow’s milk allergy (CMA).1 For new preparation instructions, please read the tin carefully. Available from September 2015. Find out more at
www.nutramigen.co.ukor call Mead Johnson Carelineon 01895 230575. Nutramigen with LGG®
is not recommended for premature and immune compromised infants unless directed and supervised by a healthcare professional.
References: 1. Canani RB et al. J Pediatr 2013;163:771–777. LGG®
is a registered trademark of Valio Ltd, Finland. IMPORTANT NOTICE: Breast milk is the best nutrition for babies.
Reltebon® Actavis UK has reduced the list price ofReltebon®
OxyContin®2. Reltebon®
Prolonged-release Tablets. Reltebon® Prolonged-release Tablets are indicated in severe pain that can be adequately managed only with opioid analgesics1 Reltebon®
(oxycodone hydrochloride) .
Prolonged-release Tablets are now available at half the price of Prolonged-Release tablets are available in eight
strengths: 5mg x 28, 10mg x 56, 15mg x 56, 20mg x 56, 30mg x 56, 40mg x 56, 60mg x 56 and 80mg x 561. Manufactured in the Actavis facility based in North Devon, Reltebon®
Prolonged-release Tablets are bio-equivalent to OxyContin®3 January 2015, 42% of oxycodone tablets were generically prescribed in the UK4
As a leading supplier of generic pharmaceuticals, Actavis currently markets more than 650 generic products in the UK, and has approximately 85 additional products under registration and development. The combination with Auden Mckenzie adds approximately 175 new generic and branded products, as well as a pipeline of approximately 40 additional products, in various dosage forms, for treatments across a broad spectrum of therapeutic areas5
. Actavis is committed Budenofalk Rectal Foam
Budenofalk Rectal Foam delivers steroid therapy directly to the site of inflammation and works as effectively as hydrocortisone foam enema for Ulcerative Colitis patients (1)
.
Our patient focussed design encourages drug adherence by offering the benefits of a soft,pre-lubricated, flexible, disposable nozzle combined with a high drug concentration in a low volume of foam; preferred by patients to liquid enemas. (2) effective than prednisolone steroid foam.
Budenofalk Foam is more cost
Budenofalk 2mg x14 actuations cost £57.11 vs Prednisolone 20mg rectal foam x14 actuations costs £78.00 (3)
1. Bar-Meir S et al. Dis Colon Rectum 2003; 46: 929–36. 2. Gross V et al. Alimet Pharmacol Ther 2006; 23: 303–12.
to offering pharmacists the best value on its extensive portfolio, which includes its franchise of pain products. Jonathan Wilson, Managing Director at Actavis UK comments: “The pain franchise is an important part of the Actavis UK business and we are committed to offering a market competitive price to both pharmacists and the NHS. Having listened to our customers’ needs we are now offering further value by reducing the list price of Reltebon®Prolonged-release tablets, with effect from January 2016.” The Reltebon®
Prolonged-release Tablet
range is available through all major wholesalers, or directly from the Actavis Telemarketing Team on Freephone: 0800 731 0370 or by fax: 0800 731 0380.
Product Strength
Prolonged-Release Tablet
PIP
Reltebon® (Oxycodone 5mg Hydrochloride)
10mg 15mg 20mg 30mg 40mg 60mg 80mg
Code Pack Size
386-3487 28 386-3495 56 393-3728 56 386-3503 56 393-3736 56 386-3511 56 393-3744 56 386-3529 56
NHS List Price Drug Tariff6 £6.26
£12.52 £19.06 £25.04 £38.11 £50.09 £76.24
£100.19
£12.52 £25.04 £38.12 £50.08 £76.23
£100.19 £152.49 £200.39
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Actavis on 01271 385257 or by email at
medinfo@actavis.co.uk UK/RE/0061/12-15 Date of Preparation January 2016
1. Actavis UK Ltd. Reltebon® SmPC 2014 2. Monthly Index of Medical Specialities (MIMs) December 2015. 3. Actavis UK Ltd. Data on file UK/RE/0016/04-15 4. Actavis UK Ltd. Data on file UK/RE/0014/04-15 5. Actavis Completes Acquisition of Auden McKenzie – June 2015 Available at
www.actavis.co.uk/en-gb/news/news/actavis-completes-acquisition-of-auden-mckenzie 6. NHS Electronic Drug Tariff Part VIIIA Products O. December 2015. Accessed by
www.drugtariff.nhsbsa.nhs.uk
. In .
pharmacyinfocus.co.uk 51
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64